BMY — Bristol-Myers Squibb Company
In 2026 Q2, 17 of the 140 tracked hedge funds reported a position in Bristol-Myers Squibb Company (BMY), worth $665.93M combined. Over the quarter 7 opened or added, 5 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| VanEck | $588.74M | 0.36% | -0.4% |
| Oaktop | $27.66M | 1.20% | NO CHANGE |
| ARS | $17.81M | 0.78% | +1% |
| Colrain | $11.99M | 4.10% | +2.8% |
| IMC | $7.38M | 0.07% | NEW |
| Four Tree Island | $3.36M | 1.10% | NO CHANGE |
| Quadrature | $1.96M | 0.02% | -79.8% |
| Pingora | $1.95M | 1.10% | NO CHANGE |
| Chapin Davis | $1.23M | 0.22% | -0.7% |
| Parvin | $1.11M | 0.89% | +2.6% |
| Navellier | $694.38K | 0.06% | +52.5% |
| KRS | $680.40K | 0.32% | +0% |
| Steadtrust | $676.00K | 0.34% | NO CHANGE |
| Polymer | $379.43K | 0.06% | +9.3% |
| O'Keefe | $240.28K | 0.05% | NO CHANGE |
| Essex | $64.53K | 0.00% | NO CHANGE |
| Persistent | $2.88K | 0.00% | NEW |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.